Hypertension in Special Populations: Chronic Kidney Disease, Organ Transplant Recipients, Pregnancy, Autonomic Dysfunction, Racial and Ethnic Populations

Cardiology Clinics

Volumn 28, Issue 4, 2010, Pages 623-638

  Flack, John M ^a   Ferdinand, Keith C ^b   Nasser, Samar A ^a   Rossi, Noreen F ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

African American; Baroreceptor reflex; Hypertension; Kidney disease; Organ transplant; Pregnancy

Indexed keywords

ALISKIREN; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; IMMUNOSUPPRESSIVE AGENT; LABETALOL; METHYLDOPA; NIFEDIPINE; PLACEBO; RAMIPRIL; RENIN INHIBITOR; TELMISARTAN;

ADD ON THERAPY; AFRICAN AMERICAN; AUTONOMIC DYSFUNCTION; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETIC NEPHROPATHY; DIALYSIS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; ECLAMPSIA; EDEMA; EMOTIONALITY; ETHNIC DIFFERENCE; FETUS OUTCOME; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT REJECTION; HIGH RISK POPULATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; MATERNAL HYPERTENSION; MATERNAL TREATMENT; MONOTHERAPY; ORGAN INJURY; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; PREECLAMPSIA; PREGNANCY; PRESSORECEPTOR; PRIORITY JOURNAL; PROTEINURIA; RACE DIFFERENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM RESTRICTION; TERATOGENICITY; VASCULAR DISEASE;

AFRICAN AMERICANS; ANTIHYPERTENSIVE AGENTS; AUTONOMIC NERVOUS SYSTEM DISEASES; BAROREFLEX; BLOOD PRESSURE MONITORING, AMBULATORY; COMBINED MODALITY THERAPY; COMORBIDITY; FEMALE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; HYPERTENSION, RENAL; KIDNEY TRANSPLANTATION; MALE; POSTOPERATIVE COMPLICATIONS; PREGNANCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 77957725142     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2010.07.007     Document Type: Review

References (98)

1. Available at:, Accessed March 19, 2010. http://www.kidney.org/professionals/KDOQI/guidelines_bp/index.htm.
2. Manjunath G., Tighiouart H., Coresh J., et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003, 41:47-55.
3. Franklin S.S., Jacobs M.J., Wong N.D., et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001, 37:869-874.
4. Snyder J.J., Foley R.N., Collins A.J. Prevalence of CKD in the United States: a sensitivity analysis using the National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 2009, 53(2):218-228.
5. Coresh J., Wei G.L., McQuillan G., et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2001, 161:1207-1216.
6. Hillege H.L., Fidler V., Diercks G.F., et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002, 106:1777-1782.
7. Flack J.M., Duncan K., Ohmit S.E., et al. Influence of albuminuria and glomerular filtration rate on blood pressure response to antihypertensive drug therapy. Vasc Health Risk Manag 2007, 3(6):1029-1037.
8. Nasser S.A., Lai Z., O'Connor S., et al. Does earlier attainment of blood pressure goal translate into fewer cardiovascular events?. Curr Hypertens Rep 2008, 10(5):398-404.
9. Weir M.R. Hypertension and the kidney: perspectives on the relationship of kidney disease and cardiovascular disease. Clin J Am Soc Nephrol 2009, 4(12):2045-2050.
10. Jafar T.H., Schmid C.H., Landa M., et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001, 135:73-87.
11. Jafar T.H., Stark P.C., Schmid C.H., et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and agniotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003, 139:244-252.
12. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
13. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997, 349:1857-1863.
14. Hoogwerf B.J. Renin-angiotensin system blockade and cardiovascular and renal protection. Am J Cardiol 2010, 105(Suppl 1):30A-35A.
15. Lewis E.J., Hunsicker L.G., Bain R.P., et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456-1462.
16. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
17. Wright J.T., Bakris G., Greene T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002, 288:2421-2431.
18. Wright J.T., Agodoa L., Contreras G., et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med 2002, 162:1636-1643.
19. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
20. Bakris G.L., Sarafidis P.A., Weir M.R., et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized controlled trial. Lancet 2010, 375(9721):1173-1181.
21. Mann J.F., Schmieder R.E., Dyal L., et al. TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med 2009, 151:1-10.
22. Mann J.F., Schmeider R.E., McQueen M., et al. Renal outcomes with telmisaran, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372(9638):547-553.
23. Kolesnyk I., Struijk D.G., Dekker F.W., et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with chronic kidney disease. Neth J Med 2010, 68(1):15-23.
24. Parving H.H., Persson F., Lewis J.B., AVOID Study Investigators, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433-2446.
25. Karlsson J., Pivodic A., Aguirre D., et al. Efficacy, safety, and tolerability of the cyclooxygenas-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee. J Rheumatol 2009, 36:1290-1297.
26. Available at:, or, Accessed March 19, 2010. http://www.cdc.gov/nchs/data/hus/hus09.pdf.
27. Malyszko J., Małyszko J., Bachórzewska-Gajewska H., et al. Inadequate blood pressure control in most kidney transplant recipients and patients with coronary artery disease with and without complications. Transplant Proc 2009, 41(8):3069-3072.
28. Prasad G.V., Huang M., Nash M.M., et al. Role of dietary salt intake in posttransplant hypertension with tacrolimus-based immunosuppression. Transplant Proc 2005, 37(4):1896-1897.
29. Sanchez-Lazaro I.J., Martínez-Dolz L., Almenar-Bonet L., et al. Predictor factors for the development of arterial hypertension following heart transplantation. Clin Transplant 2008, 22(6):760-764.
30. Aliabadi A.Z., Zuckermann A.O., Grimm M. Immunosuppressive therapy in older cardiac transplant patients. Drugs Aging 2007, 24(11):913-932.
31. Kobashigawa J.A., Patel J., Furukawa H., et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant 2006, 25(4):434-439.
32. Patel J.K., Kobashigawa J.A. Tacrolimus in heart transplant recipients: an overview. BioDrugs 2007, 21(3):139-143.
33. Morales J.M., Dominguez-Gil B. Impact of tacrolimus and mycophenolate mofetil combination on cardiovascular risk profile after kidney transplantation. J Am Soc Nephrol 2006, 17(12 Suppl 3):S296-S303.
34. Ye F., Ying-Bin X., Yu-Guo W., et al. Tacrolimus versus cyclosporine microemulsion for heart transplant recipients: a meta-analysis. J Heart Lung Transplant 2009, 28(1):58-66.
35. Roche S.L., Kaufmann J., Dipchand A.I., et al. Hypertension after pediatric heart transplantation is primarily associated with immunosuppressive regimen. J Heart Lung Transplant 2008, 27(5):501-507.
36. Report of the National High Blood Pressure Education Program (NHBPEP) Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000, 183(1):S1-22.
37. Chang J., Elam-Evans L.D., Berg C.J., et al. Pregnancy-related mortality surveillance-United States, 1991-1999. MMWR Surveill Summ 2003, 52(2):1-8.
38. Friedman E.A., Neff R.K. Pregnancy, hypertension: a systemative evaluation of clinical diagnostic criteria 1977, PSG Publishing, Littleton (MA).
39. Page E.W., Christianson R.E. The mean impact of mean arterial pressure in the middle trimester on the outcome of pregnancy. Am J Obstet Gynecol 1976, 125:740-746.
40. Hedderson M.M., Ferrara A. High blood pressure before and during early pregnancy is associated with an increased risk of gestational diabetes mellitus. Diabetes Care 2008, 31(12):2362-2367.
41. Clapp J., Capeless E. Cardiovascular function before, during and after the first and subsequent pregnancies. Am J Cardiol 1997, 80:1469.
42. Chronic Hypertension in Pregnancy ACOG Practice Bulletin No. 29. American College of Obstetricians and Gynecologists. Obstet Gynecol 2001, 98:177-185.
43. Podymow T., August P. Hypertension in pregnancy. Adv Chronic Kidney Dis 2007, 14(2):178-190.
44. Lindheimer M.D., Taler S.J., Cunningham F.G. Hypertension in pregnancy. J Am Soc Hypertens 2010, 4(2):68-78.
45. Mongraw-Chaffin M.L., Cirillo P.M., Cohn B.A. Preeclampsia and cardiovascular disease death. prospective evidence from the child health and development studies cohort. Hypertension 2010, 56:166-171.
46. Hladunewich M., Karumanch S.A., Lafayette R. Pathyophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol 2007, 2:543-549.
47. Lindheimer M.D., Conrad K.P., Karumanchi S.A. Renal physiology and disease in pregnancy. Seldin and Giebisch's the kidney: physiology and pathophysiology 2008, 2339-2398. Academic Press, Elsevier, San Diego (CA). 4th edition. R.J. Alpern, S.C. Herbert (Eds.).
48. Khalil A., Jauniaux E., Harrington K. Antihypertensive therapy and central hemodynamics in women with hypertensive disorders in pregnancy. Obstet Gynecol 2009, 113(3):646-654.
49. Magee L.A., Ornstein M.P., von Dadelszen P. Fortnightly review: management of hypertension in pregnancy. BMJ 1999, 318(7194):1332-1336.
50. Von Dadelszen P., Magee L.A. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: an updated metaregression analysis. J Obstet Gynaecol Can 2002, 24:941-945.
51. Abalos E., Duley L., Steyn D.W., et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2007, 1. CD002252.
52. Jones D.C., Hayslett J.P. Outcome of pregnancy in women with moderate or severe renal insufficiency. N Engl J Med 1996, 335(4):226-232.
53. Easterling T.R., Carr D.B., Brateng D., et al. Treatment of hypertension in pregnancy: effect of atenolol on maternal disease, preterm delivery, and fetal growth. Obstet Gynecol 2001, 98(3):427-433.
54. McCowan L.M., Buist R.G., North R.A., et al. Perinatal morbidity in chronic hypertension. Br J Obstet Gynaecol 1996, 103(2):123-129.
55. Khedun S.M., Maharaj B., Moodley J. Effects of antihypertensive drugs on the unborn child. What is known, and how should this influence prescribing?. Paediatr Drugs 2000, 2(6):419-436.
56. Sica D.A. Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich) 2007, 9(5):399-405.
57. Small M.J., Hayslett J.P. Chronic hypertension in pregnancy. High risk obstetrics: the requisites in obstetrics and gynecology 2008, 241-256. Mosby, Philadelphia. M.I. Evans, E.F. Funai, C.J. Lockwood (Eds.).
58. Sibai B.M. Hypertension. Obstetrics: normal and problem pregnancies 2007, 863-912. Elsevier, Philadelphia. S.G. Gabbe, J.R. Niebyl, J.L. Simpson (Eds.).
59. Ferrer R.L., Sibai B.M., Mulrow C.D., et al. Management of mild chronic hypertension during pregnancy: a review. Obstet Gynecol 2009, 6(5 Pt 2):849-860.
60. Sibai B.A., Mabie W.C., Shamsa F., et al. A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol 1990, 162:960-967.
61. Lip G.Y.H., Beevers M., Churchill D., et al. Effect of atenolol on birth weight. Am J Cardiol 1997, 79:1436-1438.
62. Lydakis C., Lip G.Y.H., Beevers M., et al. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens 1999, 12:541-547.
63. Sibai B.M., Grossman R.A., Grossman H.G. Effects of diuretics on plasma volume in pregnancies with long-term hypertension. Am J Obstet Gynecol 1984, 150(7):831-835.
64. Cooper W.O., Hernandez-Diaz S., Arbogast P.G., et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006, 354(23):2443-2451.
65. Robertson D., Beck C., Gary T., et al. Classification of autonomic disorders. Int Angiol 1993, 12(2):93-102.
66. Ketch T., Biaggioni I., Robertson R., et al. Four faces of baroreflex failure: hypertensive crisis, volatile hypertension, orthostatic tachycardia, and malignant vagotonia. Circulation 2002, 105(21):2518-2523.
67. Floras J.S., Aylward P.E., Victor R.G., et al. Epinephrine facilitates neurogenic vasoconstriction in humans. J Clin Invest 1988, 81(4):1265-1274.
68. Eisenhofer G., Friberg P., Goldstein D.S., et al. Differential actions of desipramine on sympathoadrenal release of noradrenaline and adrenaline. Eur J Clin Pharmacol 1995, 40:263-265.
69. Timmers H.J., Wieling W., Karemaker J.M., et al. Baroreflex failure: a neglected type of secondary hypertension. Neth J Med 2004, 62:151-155.
70. Jordan J., Shannon J.R., Black B.K., et al. Malignant vagotonia due to selective baroreflex failure. Hypertension 1997, 30:1072-1077.
71. Zar T., Peixoto A.J. Paroxysmal hypertension due to baroreflex failure. Kidney Int 2008, 74(1):126-131.
72. Heusser K., Tank J., Luft F.C., et al. Baroreflex failure. Hypertension 2005, 45:834-839.
73. Muntner P., He J., Cutler J.A., et al. Trends in blood pressure among children and adolescents. JAMA 2004, 291(17):2107-2113.
74. Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119(3):480-486.
75. Cooper R.S., Wolf-Maier K., et al. An International comparative study of blood pressure in populations of European vs. African descent. BMC Med 2005, 3:2.
76. Cutler J.A., Sorlie P.D., Wolz M., et al. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008, 52(5):818-827.
77. Giles T., Aranda J.M., Suh D.C., et al. Ethnic/racial variations in blood pressure awareness, treatment, and control. J Clin Hypertens (Greenwich) 2007, 9(5):345-354.
78. Hughes J.W., Kobayashi I., Deichert N.T. Ethnic differences in sleep quality accompany ethnic differences in night-time blood pressure dipping. Am J Hypertens 2007, 20:1104-1110.
79. Flack J.M., Staffileno B.A. Hypertension in blacks. Hypertension: a companion to Brenner and Rector's the kidney 2000, 558-563. WB Saunders, Philadelphia (PA). S. Oparil, M.A. Weber (Eds.).
80. Flack J.M., Ensrud K.E., Mascioli S., et al. Racial and ethnic modifiers of the salt-blood pressure response. Hypertension 1991, 17(Suppl 1):I115-I121.
81. Schmidlin O., Forman A., Tanaka M., et al. NaCl-induced renal vasoconstriction in salt-sensitive African Americans: antipressor and hemodynamic effects of potassium bicarbonate. Hypertension 1999, 33(2):633-639.
82. Schmidlin O., Sebastian A.F., Morris R.C. What initiates the pressor effect of salt in salt-sensitive humans? Observations in normotensive blacks. Hypertension 2007, 49(5):1032-1039.
83. Heffernan K.S., Jae S.Y., Wilund K.R., et al. Racial differences in central blood pressure and vascular function in young men. Am J Physiol Heart Circ Physiol 2008, 295(6):H2380-H2387.
84. Din-Dzietham R., Couper D., Evans G., et al. Arterial stiffness is greater in African Americans than in whites: evidence from the Forsyth County, North Carolina, ARIC cohort. Am J Hypertens 2004, 17(4):304-313.
85. Stein C.M., Lang C.C., Nelson R., et al. Vasodilation in black Americans: attenuated nitric oxide-mediated responses. Clin Pharmacol Ther 1997, 62(4):436-443.
86. Stein C.M., Lang C.C., Singh I., et al. Increased vascular adrenergic vasoconstriction and decreased vasodilation in blacks. Additive mechanisms leading to enhanced vascular reactivity. Hypertension 2000, 36(6):945-951.
87. D'Agostino R.B., Burke G., O'Leary D., et al. Ethnic differences in carotid wall thickness. The Insulin Resistance Atherosclerosis Study. Stroke 1996, 27(10):1744-1749.
88. Zion A.S., Bond V., Adams R.G., et al. Low arterial compliance in young African-American males. Am J Physiol Heart Circ Physiol 2003, 285(2):H457-H462.
89. Wong T.Y., Klein R., Duncan B.B., et al. Racial differences in the prevalence of hypertensive retinopathy. Hypertension 2003, 41(5):1086-1091.
90. Flack J.M., Neaton J.D., Daniels B., et al. Ethnicity and renal disease: lessons from multiple risk factor intervention trial and the treatment of mild hypertension study. Am J Kidney Dis 1993, 21(Suppl 4):31-40.
91. Mensah G.A., Mokdad A.H., Ford E.S., et al. State of disparities in cardiovascular health in the United States. Circulation 2005, 111:1233-1241.
92. Plantinga L.C., Miller E.R., Stevens L.A., et al. Blood pressure control among persons without and with chronic kidney disease: US trends and risk factors 1999-2006. Hypertension 2009, 54:47-56.
93. Cushman W.C., Ford C.E., Cutler J.A., et al. ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 2002, 4(6):393-404.
94. Boddi M., Poggesi L., Coppo M., et al. Human vascular renin-angiotensin system and its functional changes in relation to different sodium intakes. Hypertension 1998, 31(3):836-842.
95. Price D.A., Fisher N.D., Osei S.Y., et al. Renal perfusion and function in healthy African Americans. Kidney Int 2001, 59(3):1037-1043.
96. Mokwe E., Ohmit S.E., Nasser S.A., et al. Determinants of blood pressure response to quinapril in black and white hypertensive patients: the Quinapril Titration Interval Management Evaluation trial. Hypertension 2004, 43(6):1202-1207.
97. Sehgal A.R. Overlap between whites and blacks in response to antihypertensive drugs. Hypertension 2004, 43(3):566-572.
98. Flack JM, Sica DA, Bakris G, et al. International Society on Hypertension in Blacks (ISHIB) consensus statement on the treatment of hypertension in African Americans. Hypertension, in press.